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ABSTRACT

Compositions containing as the active ingredient a spin

trapping reagent, preferably a-phenyl butyl nitrone
(PBN) or spin-trapping derivatives thereof, in a suitable
pharmaceutical carrier for administration to a patient
are disclosed for treating or preventin symptoms associ
‘ated with aging or other conditions associated with

oxidative tissue damage. Other spin-trapping agents can
also be used, suchas 5,5-dimethyl pyrroline N-oxide
(DMPO) or a-(4-pyridyl l-oxide)-N-tert-butylnitrone
(POBN), and other spin-trapping derivatives thereof.
These compositions and methods are useful in the treat

ment of age-related disorders, pre-surgical and/or pre
anesthetic preparation or administration of chemothera-.
peutic agents, and in the treatment of disorders or

trauma of the brain, cardiovascular system, and lym
phatic system. Studies in animals demonstrate that ad
ministration of compound for a two week period re
duces the level of oxidized brain enzymes ot normal and
restores memory to the sam level as tested ‘in young
control animals.
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PBN, DMPO, AND POBN COMPOSITIONS AND
METHOD OF USE THEREOF FOR INHIBITION
OF AGE-ASSOCIATED OXIDATION
This is a continuation of application Ser. No.

2

cules within neurons throughout the central nervous
system. The hypothesis is that cells which have a

buildup of oxidized protein are less functional and less
able to maintain the speci?ed role of those cells in that
5 particular area of the central nervous system. While this

hypothesis has been suggested by several investigators,

07/589,177, ?led on Sep. 27, 1990, now abandoned,
which is a continuation-in-part of US. Ser. No.

there are no reports of substantial investigations in

which alterations in the oxidized protein burden of the

07/422,651, entitled “Phenyl Butyl Nitrone Composi

central nervous system was manipulated and correlated
tions for Treatment of Oxidative Tissue Damage” ?led 10 with a functional outcome on the part of the animal.

Oct. 17, 1989, by John M. Carney and Robert A. Floyd
issued Jun. 18, 1991, as U.S. Pat. No. 5,025,032.

Such an approach, if truly associated with brain dys
function, would provide a basis for reversing the age

BACKGROUND OF THE INVENTION
The present invention is a method and compositions

related neuronal de?cit of cells that are still viable.
Thus, such an approach is targeted at cells which are

marginally functional but still viable.
It is therefore the object of the present invention to
provide composition and methods for the use in pre
venting or reversing age related functional de?cits.
It is further the object of the present invention to
provide composition and methods for use thereof which
are useful in preventing and reversing cognitive de?cits

containing spin trapping agents for the treatment of age
related dysfunctions and other conditions arising from

oxidative damage.
Age related changes in central nervous system func
tion have generally been associated with the loss of
cells, a widening of lateral ventricles and de?cits in
short term memory. The precise mechanisms of func

associated with infection or in?ammation.

tional changes as a result of aging, or other diseases

It is another object of the present invention to pro

associated with aging, have not generally been agreed
upon.

25

Several mechanisms for the generation of oxidized
material in the brain have been proposed. In particular,
transition metals, especially iron and copper, have been
suggested as mediating aspects of this oxidation. A
marked reduction in certain neurotransmitter receptor
systems has been associated with increased oxidation of
proteins. For example, decreases in muscarinic recep
tors and other cholinergic systems have been character
ized as they relate to alterations in functions in Alzhei
mers disease. It has also been hypothesized that aging is

associated with multiple minor periods of ischemia
(multi-infarct conditions or transient ischemia attacks)

vide composition and methods reducing post traumatic

cognitive dysfunction.
SUMMARY OF THE INVENTION
Compositions containing as the active ingredient a

spin-trapping reagent, preferably a-phenyl butyl ni
trone (PBN), or spin-trapping derivatives thereof, in a
suitable pharmaceutical carrier for administration to a

patient, are disclosed for treating or preventing symp
toms associated with aging or other conditions, associ
ated with oxidative tissue damage. The preferred PBN

compositions have the following general formula:

which, over a period of time, may give rise to the pro

H

duction of oxidized protein.
Changes associated with ischemic brain disease have 40
been proposed to be the result of alterations in calcium
disposition, increase in excitoxic neurotransmitter re
lease, production of free radicals and the attendant aci
dosis that results in an increase in the loosely bound
metals in the cell that are catalytic for the generation of
oxygen free radicals. These changes are largely limited
to neuronal elements. Reactive gila have been demon

0

C=N+
X

Y

wherein:
X is phenyl or
(0K)”

strated, however, they are mostly associated with post
neuronal damage.
The treatment of age related dementias have been

largely limited by the inability to develop an appropri

wherein
ate model for the study of this condition. This is due to
R is H,
the fact that aging is a very complicated condition
which is dif?cult to model, especially with the lack of
0
speci?c information associated with the functional and
ll
/
biochemical basis of human age related dementias. The
Z—C-, or Z; or —CH=N
,
use of animal models has largely depended upon model
\
Y
systems used in brain studies, where the brains'are not
truly senescent, or the use of senescent animals, with
little understanding of the origin of the senescence or, in 60 and n is a whole integer from 1 to 5; or
some cases, the inability to demonstrate truly functional
senescence.

The demonstration in a variety of systems, both neu
ral and nonneural, that there is an age related enhance~

ment of the level of oxidized protein in tissue gives rise 65
to the possibility that age related dysfunctions in the
central nervous system may be associated with the

build-up of oxidized proteins and oxidized macromole

Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

5,405,874
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of 32 mg PBN/kg (i.p.). Each histogram is the mean of
three subjects.

.

FIGS. 3A, 3B and 3C are graphs comparing changes

in protein carbonyl (pmol/mg protein) (FIG. 3A), glu
tamine synthetase (FIG. 3B), and protease activity (%
control) (FIG. 3C) over days following termination of
twice daily dosing with 10 mg PBN/kg body weight.
FIG. 3A represents the level of carbonyl in the soluble
protein obtained from gerbils treated for fourteen days
10 and tested at l, 3, 7 and 14 days post dosing. FIG. 3B is

the time related decrease in cortical glutamine synthe

tase (GS) activity after termination of twice daily injec
tions of PBN. FIG. 3C demonstrates the‘ time related

decrease in alkaline protease activity following termina
tion of twice daily injections of PBN. Each histogram is

Z is a C1 to C5 straight or branched alkyl group.
Other spin-trapping agents can also be used, such as

5,5-dimethylpyrroline-N-oxide (DMPO) or -(4-pyridyl
l-oxide) N-tert-butyl nitrone (POBN), and other spin
trapping derivatives thereof.
In the preferred embodiment, the compositions are
administered one to two times daily by oral administra
tion, at a dosage equivalent to between one and ten

milligrams PBN/70 kg of human body weight. Studies

the mean i standard error (SE) of three subjects at
each of the indicated times. The asterisk and dashed line
indicates the old gerbil, untreated control values for
each of the measures.
20

FIG. 4A, 4B and 4C are graphs comparing changes in

protein carbonyl (pmol/mg protein) (FIG. 4A), gluta
mine synthetase (FIG. 4B), and protease activity (%
control) (FIG. 4C) over days following termination of
twice daily dosing with 32 mg PBN/kg body weight.

in animals demonstrate that administration of com 25 FIG. 4A represents the level of carbonyl in the soluble
pound for a two week period reduces the level of oxi
protein obtained from gerbils treated for fourteen days
dized brain enzymes to normal and restores memory to
and tested at l, 3, 7 and 14 days post dosing. FIG. 4B is

the same level as tested in young control animals. A

signi?cant reduction in oxidized proteins and memory
recovery is observed as early as seven days after initia
tion of treatment; levels are still comparable to young
controls one to three days following cessation of treat

ment, and partially reduced at seven days following
cessation of treatment.
These compositions and methods are useful in the

treatment of age-related disorders, pre-surgical and/or
pre-anesthetic preparation or administration of chemo
therapeutic agents, and in treatment of disorders or
trauma of the brain, cardiovascular system, lymphatic
system, and, potentially, in the treatment of some viral
disorders characterized by oxidation of host proteins in
cells infected by the virus.

the time related decrease in cortical glutamine synthe
tase (GS) activity after termination of twice daily injec
tions of PBN. FIG. 4C demonstrates the time related

decrease in alkaline protease activity following termina
tion of twice daily injections of PBN. Each histogram is
the mean t SE. of three subjects at each of the indi
cated times. The asterisk and dashed line indicates the
old gerbil, untreated control values for each of the mea
sures.

FIG. 5 is a graph of the eight arm radial arm maze

performance of young or old gerbils treated with either
saline or PBN. Gerbils were placed into the central
compartment of the maze with the barrier in place to
limit exploration. After the barrier was removed, the
number of arms re-entered and the total elapsed time
before all eight arms were entered was recorded. Each

BRIEF DESCRIPTION OF THE FIGURES
histogram represents the mean i- of 18 gerbils. The
FIG. 1 is a graph of the alkaline protease activity 45 animals were administered PBN twice daily (either 10
or 32 mg PBN/kg body weight) for seven'days and
from gerbil cortex (% of young, three to four month old
tested at the end of seven days of dosing.
gerbil cortex) for young gerbils (age three to four
months), old gerbils (retired breeders of twelve to ?f
DETAILED DESCRIPTION OF THE
teen months of age), old gerbils that received twice
INVENTION
50

daily injections of 0.1 ml saline/kg body weight, and old
gerbils that received twice daily injections of 10 mg
PBN in saline/kg body weight for two weeks. Protease
activity was determined using oxidized protein ex
tracted from young gerbil cerebral cortex.
FIG. 2A and FIG. 2B are graphs comparing protein

carbonyl activity (pmol/mg protein) (FIG. 2A) and
glutamine synthetase activity (FIG. 2B) in the cerebral
cortex (neocortex) of young adult and old gerbils over

It has now been discovered that, further to the meth

ods using PBN for the treatment and prevention of
ischemic damage described and claimed in US. Ser.

No. 07/422,651 ?led Oct. 17, 1989, spintrapping agents
are useful in preventing or treating symptoms associ
ated with aging, trauma, drug administration and sur
gery, especially of the brain. As used herein, a free
radical scavenger or spin-trap reagent is a molecule that
will form a stable complex spin adduct spin-adduct of a

days of administration of 32 mg PBN/kg administered 60 carbon with a free radical. A free radical is a molecule

twice a day and assayed at one, three, seven or fourteen

days. At the end of each of the days indicated, animals
were decapitated and cerebral cortex removed and

rapidly frozen in liquid nitrogen. Protein carbonyl con

in which the free radical is localized on a carbon atom.

As a result of this chemical bond formation, the free
radical is no longer damagingto the cell. In combina
tion with a pharmaceutical vehicle suitable for adminis

tent was determined using the DNPH procedure. The 65 tration to a patient, preferably by oral administration,
results demonstrate the reduction in oxidative damage
these compounds are useful in preventing or reversing
to proteins and the loss of enzyme activity in gerbil
symptoms associated with aging, for example, increased
cerebral cortex as a result of twice daily administration

levels of oxidized proteins, decreased enzymatic activ

5,405,874
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ity, and loss in spatial and short term memory. Cur
rently, there are no effective, non-toxic treatments for

OW

aging, Effectiveness has been demonstrated in animals
after as few as seven days of administration. Effective
ness continues for at least one week after administration.
Values return to pretreatment levels after two weeks.

wherein
W is

Useful Spin-trapping compounds
PBN and derivatives thereof

10

The preferred spin-trapping compounds are a-phenyl

ll

t-butyl nitrone (PBN), and derivatives thereof. PBN has

c-cm,

O

0

II

II

-NH—C—Z, c-oz,

no measurable effect on normal or uninjured cells. PBN

or Z; and
Z is a C1 to C5 straight or branched alkyl group.

is the preferred compound at this time, although a num

ber of derivatives are also useful, including hydroxy
derivatives, especially 2-, 3- or 4-hydroxy PBN and
mono-, di- and trihydroxy tert-butyl nitrone; esters,
especially esters which release 2-, 3, or 4-hydroxyphe
nyl t-butyl nitrone such as the acetoxy derivative, 2-, 3-,
or 4-carboxyphenyl t-butyl nitrone, such as the ethyl
derivative, or phenyl hydroxybutyl nitrone, such as the

standard techniques, for example, for substitution of the '

acetoxy derivative; alkoxyl derivatives, especially alk

methyl groups.The general formula for DMPO is:

Other spin-trapping reagents
Other spin-trapping agents can also be used, such as

5,5-dimethyl pyrroline N-oxide (DMPO) or a-(4-pyri

dyl 1-oxide)-N-tertbutylnitrone (POBN), and spin-trap
ping derivatives thereof. Derivatives are made using

oxyl derivatives which release 2-, or 4-hydroxyphenyl
t-butyl nitrone, such as the methyl derivative; and acet
amide derivatives, especially acetamide derivatives
which release 2-, or 4 aminophenyl t-butyl nitrone, such
as the acetyl derivative; diphenyl nitrone (PPN) and the
analogous diphenyl nitrone derivatives. As used herein,
“PBN” refers to both phenyl t-butyl nitrone and deriva
tives thereof, unless otherwise stated.
The general formula for PBN and useful derivatives
thereof is:

so
B i
0

wherein
A and B are independently CH3, CHZOH, CHZOW,
35

H

or

O

(OWL,

C=N+
X

Y

wherein:
X is phenyl or

n is an integer from 1 to 5
45

wherein
W is

(01K)”
O

0

II

II

II

—C—CH3, —NH--C—Z, —c—0Z,
50

wherein

or Z ; and

Z is a C1 to C5 straight or branched alkyl group.
The general formula for POBN is:

R is H,
0

O

55
Y

and n is a whole integer from 1 to 5; or

i

65

wherein
Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

5,405,874
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dation of the RNA or regulatory macromolecules, or

the rate of protein degradation may be altered.
Any of these changes could negatively impact on the
acquisition consolidation and retrieval of information,
even by interference with a single step in the learning
and memory process. It is possible that oxidation of cells
in a particular brain region could result in acquisition
de?cits, whereas oxidation of a different region could
result in output de?ciency. Considering the number of

devastating neurodegenerative diseases, including Alz
heimer’s disease, this treatment could potentially be a

tremendous help to people with these disorders.
Examples of other disorders that can be treated with
15

these compositions include peripheral neuropathy of
diabetes, exercise induced muscle damage and pain, and
enhancement of cellular response to hormonal signals.

Treatment of neurodegenerative disorders
20

n is a whole number from 1 to 4, or

Several neurodegenerative conditions are most ap

propriately treated by compounds that interfere with
protein oxidation. Alzheimer’s disease has been associ

ated with the accumulation of abnormal oxidized prote
ins or the production of abnormal proteins in areas that
25 are pathologically affected. In addition, age related
enhancement in protein oxidation occurs in all cells in
the aged individual. PBN and derivatives thereof have
been demonstrated to be useful in the reduction in pro
tein oxidation and in the increase in the activity of criti
Z is a C1 to C5 straight or branched alkyl group.
cal enzymes within the brain of aged animals. Since this
is
a fundamental change in oxidative state, it is likely
Indications that the compositions are useful in treating
that PBN and other related compounds would be useful
The free-radical scavenger compositions are useful in
when given chronically to individuals who are in the
treating a variety of dysfunctions or disorders charac
early phases, or possibly in the late phases, of Alzhei
terized by oxidized proteins in the tissues or cells. Oxi 35 mer’s disease. In addition, multiinfarct dementias should
dation of cytosolic protein has been demonstrated to
be treatable with these compounds, since they also deal
occur in a wide variety of pathological conditions. dAc
with ischemia reperfusion oxidation issues.
cordingly, compounds which have as their fundamental
Senile dementia has not been directly evaluated for
mechanism of action the interference of production of
ischemia reperfusion etiology or protein oxidation,
oxidized protein should be useful in the treatment of a 40 however, it is likely that senile dementia would also be
wide variety of diseases having what appears at ?rst
treatable with these compounds. This is based on the
glance to be widely dissimilar etiologies, because the
hypothesis that advanced age is associated with in
fundamental cause of the condition is oxidation of pro
creased production of oxidized protein. In progeria, a
tein or nucleic acids.

In one embodiment, the spin-trapping agent is admin 45 unique condition in which aging is accelerated, Stadt
man and colleagues at the NIH have demonstrated that
there
is a marked increase in the base-level of oxidized
function of age. Preliminary results indicate that there is
protein even in young adult subjects with progeria, as
a net increase in the oxidation of proteins and the accu
reported by Oliver, et al., J. Biol. Chem. 262, 5488-5491
mulation of oxidized material in the brain. The develop
ment of senil plaque is also routinely observed in aged 50 (1987) and Starke-Reed and Oliver, Arch. Biochem.
Biophys. 275, 559-567 (1989). While this is a rare condi
patients.
tion it should also be treatable with these compositions.
Other disorders are those resulting from trauma, such
Another condition which is likely to be associated
as a blow to the head, or from drug treatment, for exam
with oxidative damage arising from microcirculatory '
ple, administration of anesthesia or drug abuse, or even
istered to a patient to reverse the damage occurring as a

as a result of some types of viral infections.

55

difficulties is the diabetic peripheral neuropathies and

vascular change. These are tragic conditions in which
amputation is eventually necessary in order to save the
patient. While these compounds are not likely to im
mance in a short term memory task and directly related
prove vascular flow they are likely to reduce the impact
to risk of stroke-induced damage and behavioral
change. Increased cellular oxidation may result in one 60 of transient changes in vascular flow which result in
or more of the following: (a) oxidative damage to cellu
oxidation and damage to the peripheral nerves and also
lar proteins could cause a change in the regulation of
in damage to the skeletal muscle which is often associ
ion channels, there could be a change in the rate and
ated with the condition called exercise induced or inter
ef?ciency of signal translation and membrane depolar
mittent claudication. If the retinopathy associated with
ization, signi?cant changes in energy ?uxes may occur 65 diabetes is also an ischemia reperfusion microcirculation
and compromise selective function, the ?delity of RNA
problem, then the spin-trapping compounds will be
transcription may be altered due to oxidative damage to
useful in treating the retinal damage which occurs very
DNA, RNA translation may be affected either by oxi
frequently in diabetic patients.
It has now been determined that the level of oxidized

brain protein appears to be inversely related to perfor

9
Pre-surgical preparation
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thesis.

Since the status of the cell and its survival in a hyp
oxic or anoxic environment is dependent upon the abil
ity of the cell to compartmentalize metals and handle 5
oxygen in a useful manner, in contrast to peroxidation,

it is expected that these compounds will be useful as
presurgical preparatory medication to reduce the car

bonyl load and improve the enzyme status of the patient
prior to elective surgery. These compounds would also
help the cells of the body achieve a higher level of

Effective dosages of PBN.
Exemplary dosages of PBN range from 0.1 to 10
mg/kg of body weight in animals. The effective dosage
of PBN in humans is expected to be between approxi
mately 1 and 10 mg/70 kg body weight. Toxicity tests
have demonstrated that the compound is completely
innocuous, with such low toxicity that it was not possi
ble to determine an LDS‘Q.

enzymatic function, shorten the recuperative phase, and
reduce the likelihood of any interoperative complica
tions associated with changes in microcirculation.
Treatment of viral infections and in?ammatory
disorders
Retroviruses selectively infect certain types of cells,

10

normal necessary oxidation of proteins following syn

In the preferred application, the PBN is administered
to a patient suffering from memory loss or other symp

toms frequently associated with aging. Optimum results
15 are generally observed after two weeks of daily or

twice daily oral administration. The compositions can
also be effectively administered prior to, during or

shortly after surgery, and prevent or decrease the extent
of cellular damage resulting from either the trauma or
has been the subject of much research activity is the 20 anesthesia.

such as lymphocytes. An example of a retrovirus that

Since the trapping of endogenous free radicals is
speci?c for only those cells that have been exposed to
the conditions that result in the production of free radi

human immunode?ciency virus (HIV), which causes

Acquired Immunode?ciency Syndrome (AIDS). No
means for prevention of infection has been found, al
though there have been numerous attempts to ?nd a

cals, the traps have little or no effect on normal cells.

The bene?cial effects occur only in injured cells, and do
treatment. Since activation of lymphocytes is associated
not require the presence of speci?c receptors, speci?c
with the oxidation of protein and activation of lympho
enzymes, and/or speci?c cell types.
cytes is required prior to release of newly formed vi
ruses, it is expected that administration of these compo
Methods of administration of PBN
sitions will inhibit infection and replication of lympho
30
The PBN is preferably administered systemically,
cytes by the viruses. The activation of the T4 lympho
most preferably orally, since this is the most rapid and
cyte is associated with a cascade of biochemical intra
ef?cient means for delivering the active compound to
cellular changes, one of which is the production of
the site of free radical generation. The PBN may be
oxidized protein. If PBN and/or related compounds can
administered at once, or may be divided into a number
block protein oxidation in the abnormal process then it
of smaller doses to be administered at varying intervals
is possible that PBN or other spin-trapping compounds
of time. Other methods of administration can also be
could in fact interfere with the process of viral replica
used, including subcutaneous, intravenous, and intra
tion and/or dissemination of the virus from the host cell
peritoneal
administration. The concentration of active
(T—4 lymphocyte), thereby acting as a virustatic agent
compound in the drug composition will depend on
by preventing the T4 lymphocyte from releasing the
absorption, inactivation, and excretion rates of the drug
newly formed viruses. This would be analogous to the
as well as other factors known to those skilled in the art.
The effective dosage may also be determined based on
that amount required to prevent or reverse predisposi

use of isoniazid (INH) in the treatment of tuberculosis.
At low doses INH is a tubercula static in that it reduced

the infectivity and spread of the tuberculosis, thereby
effectively protecting the patient from pulmonary dam
age.
It is important to note that the effects of the spin-trap~
ping compounds occur in animals that have a base-level
of carbonyl formation which appears to be necessary

for post translational processes. Old animals have a

signi?cantly elevated level of carbonyl protein which is
associated with decreased enzymatic function relative
to young control animals. When young control animals
are given the exact same dosage regimen, there is no

signi?cant change in enzyme activity nor is there signif
icant change in protein carbonyl. Thus the PBN and
related spin-trapping compounds are not likely to inter

tion of the cells to damage resulting from depletion of
45

ATP (as demonstrated by in vivo NMR) and damage
from free radical generation. It is to be noted that dos
age values will also vary with the condition of the pa
tient being treated. It is to be further understood that for

any particular subject, specific dosage regimens should
be adjusted over time according to the individual need
and the professional judgment of the person administer
ing or supervising the administration of the composi
tions, and that the concentration ranges set forth herein
are exemplary only and are not intended to limit the

scope or practice of the claimed composition.
A preferred mode of administration of the active
compound is in a form for oral delivery. Oral composi-‘

fere with fundamental processes that are necessary for
tions will generally include an inert diluent or an edible
the normal cellular function.
carrier. Preferred pharmaceutical carriers for intrave
In conclusion, a number of clinical conditions appear 60 nous administration are saline or phosphate buffered
to have as their fundamental cause oxidation of cellular
saline at physiological pH. Since PBN degrades at pH

protein and enzymatic damage. Spin-trapping com

pounds are effective in animal models in reducing the

protein oxidation and improving enzymatic function.

less than approximately 3 to 4, it is preferred to adminis
ter the PBN at a pH of 4 or higher, or in combination
with food, a buffering agent, or in an enteric coating.

This occurs in preparations in which the abnormal oxi 65 For oral delivery, the PBN may be enclosed in capsules,

dized protein is modi?ed and protected but the normal

post translational oxidation is allowed to occur. This
would suggest that PBN does not interfere with the

compressed into tablets, microencapsulated, entrapped
in liposomes, in solution or suspension,alone or in com
bination with a substrate immobilizing material such as

11
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starch or poorly absorbable salts such as immodium.

Pharmaceutically compatible binding agents can be

12

gerbils administered 10 mg PBN/kg body weight b.i.d.
for fourteen days.

included as part of the composition. The tablets or cap

The results demonstrate that PBN is effective in re

sules may contain, for example, any of the following

storing alkaline protease levels in old animals to those
levels present in young animals.
FIG. 2A is a graph of the changes in protein oxida
tion from brains of young and senescent gerbils, plotting
nmol protein carbonyl/mg protein versus days of treat
ment with PBN. The gerbils were given twice daily

ingredients, or compounds of a similar nature: a binder

such as microcrystalline cellulose, gum tragacanth or
gelatin; an excipient such as starch or lactose, a disinte
grating agent such as alginic acid, Primogel ®, or corn
starch; a lubricant such as magnesium stearate or Ste
rotes; a gildant such as colloidal silicon dioxide; a sweet
ening agent such as sucrose or saccharin; or a ?avoring

agent such as peppermint, methyl salicylate, or orange
?avoring. When the dosage unit form is a capsule, it can
contain, in addition to material of the above type, a
liquid carrier. In addition, dosage unit forms can contain
various other materials which modify the physical form

injections of 32 mg/kg PBN for fourteen days. Animals
were killed at one, three, seven and fourteen days and

protein carbonyl levels determined.
As can be seen in the ?gure, there is no change in the

level of oxidized protein of young gerbils treated for up
to 14 days with PBN. This indicates that the level of
oxidized protein is likely to be a natural and necessary
post translational effect, for example, if after synthesis
of the dosageunit, for example, coatings of sugar, shel
of the protein, the protein is activated by a modi?cation
lac, or other enteric agents.
involving carbonyl oxidation. In contrast to the car
The present invention- will be further understood
with reference to the following non-limiting examples 20 bonyl level seen in young animals, control aged animals
(15 months of age) have a marked increase of carbonyl
demonstrating methods for determining effectiveness of
content. This increased carbonyl content is responsive
PBN administration for treatment or prevention and/or
to treatment with PBN. Multiple days of treatment with
reversal of symptoms associated with aging.
PBN results in a progressive reduction in the level of
25 protein carbonyl to the level seen in young animals.
Example 1
Determination of brain enzyme levels in old versus

The level of protein carbonyl reduction (oxidized

young gerbils treated with PBN
A correlations between the duration of ischemia and
either the change in spontaneous behavior or the level
of oxidized brain protein has previously been demon

protein burden of neurons in the brain) is only to the
level of the normal young gerbil brain. Neither the
levels in the young gerbil brain nor the levels in the
senescent gerbil brain can be further reduced beyond
this level. This observation supports the hypothesis that

strated in gerbils. Many other psychiatric and neurolog

there is a necessary level of oxidation that occurs in

cells in normal animals, which is required for cells to
have “normal function”, and that control aged animals
been associated with oxygen radicals and the accumula 35 (15 months of age) have a marked increase of carbonyl
content. This increased carbonyl content is responsive
tion of proteins. The level of oxidized protein, gluta
ical conditions have been proposed to be the result of

oxidation. Among these conditions, cellular aging has

mine synthetase activity, brain protease activity and

to treatment with PBN. The ability of PBN to reduce

radial arm maze performance in young adult and retired

the protein carbonyl load of cells also indicates that this

breeder gerbils have now been compared and demon
strate that there is a direct relationship between the age
of the subject and the level of oxidized brain protein, as
measured using a protein carbonyl assay. Increased
levels of protein carbonyl were associated with de

is an active oxidation process which occurs at a regular
or predictable rate and that there are mechanisms exis
tent within the cells of the brain which can remove this

creased glutamine synthetase activity and decreased
alkaline protease activity. In contrast, there was no

change in acid protease activity of retired breeders,
compared to young adult gerbils. Consistent with the
age-related increase in protein oxidation and enzyme
damage, retired gerbils made signi?cantly greater num
bers of errors in a test of short-term memory, compared

to young adult gerbils. These studies demonstrate that
the functional de?cits that occur as a result of aging

oxidized protein if the process is interrupted.
FIG. 2B compares the levels of glutamine synthetase
(gs) in young and old animals and evaluates the effects
of daily administration of PBN on the speci?c activity
of the enzyme. This particular enzymatic marker has
been selected because it is a highly sensitive protein to
oxidation and because it is a metalloprotein that has
bound to it metal which may participate in the genera
tion of free radicals if the metal is dissociated with its

binding site. Glutamine synthetase activity has been
used by Stadman and colleagues (Oliver, et al., Proc.
Natl, Acad. Scie. USA 87, 5144-5147 (July 1990)) as a
marker enzyme for alterations following protein oxida

may be associated with increased protein oxidation and
decreased brain enzyme activities.
55 tion.
This system has been used to demonstrate the effec
As shown in FIG. 2B, the level of glutamine synthe
tiveness of PBN in restoring young brain enzyme levels _ tase is lower in old gerbils (1.2) than in young adult

and short term memory to old animals. The results are

gerbils (2.1). This is consistent with previous studies in
which increases in the level of the carbonyl protein
were obtained from Tumblebrook Farms, West Brook 60 (oxidized protein in cells) is associated with a decrease
?eld, Mass, weighing 50-60 grams and age three to
in glutamine synthetase activity. In particular, if the
four months. Control gerbils were given saline. Animals
glutamine synthetase enzyme is puri?ed and the car
were killed by decapitation and their brains removed
bonyl content of that enzyme is evaluated, there is a
for analysis.
marked increase in the level of oxidized protein in the
FIG. 1A is a graph of the percent alkaline protease in 65 presence of lowered glutamine synthetase activity. As
young (three to four month old) gerbils, old (twelve to
also demonstrated in FIG. 2B, repeated administration
shown in FIGS. 1 through 5, as follows. Young gerbils

?fteen month old retired breeder) gerbils, old gerbils

of PBN in young gerbils had no effect on glutamine

administered 0.1 ml saline twice daily (b.i.d.), and old

synthetase activity, providing further evidence that the

13
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level of carbonyl is associated with normal function and

and reduction in glutamine synthetase activity similar to

chronic administration of PBN has no effect on either

that which is seen in aging.
Treatment of gerbils for seven days results in a
marked alteration in the number of errors seen with old

the level of carbonyl or on the marker enzyme activity.

In contrast to the young gerbils, old gerbils given daily
injections of PBN show a time related increase in gluta

mine synthetase activity that parallels the reduction in
protein carbonyl content, indicating that the reduction
in oxidized protein burden of cells is associated with a
recovery of the enzymatic activity to the normal level
seen in young adult gerbils.
It is important to note that there is no increase in
enzymatic activity above that seen in young adult ger
bils. Thus the treatment with PBN reverses the effect of
aging on enzymatic activity but does not result in an

gerbils. Young gerbils given PBN for seven days were
not signi?cantly different from control gerbils whereas
the old gerbils given PBN for seven days showed a
marked reduction in the number of errors and returned
to the range of performance seen with control young

gerbils. Thus, there is a functional counterpart to the
biochemical changes that are seen in that reduction in

protein carbonyl and the increase in glutamine synthe
tase activity following chronic PBN treatment. This
functional counterpart is demonstrated by the number

activation of enzyme activity that exceeds the normal 15
values.
of errors seen in a short term spacial memory task, the

Example 2

radial arm maze. It should be noted that the radial arm
maze test does not require any food reinforcement or

Determination of residual effect of PBN on reduction of
20 any other reward associated with the' test. Naive ani
brain enzyme levels

As shown in FIGS. 3A, 3B, and 3C, as compared
with FIGS. 4A, 4B, and 4C, administration of 10 mg
PBN/kg is as effective as administration of 32 mg

PBn/kg body weight in restoring young enzyme levels.
The appropriate dosages and full range of effective
dosages for other species of animals can be determined
using a similar methodology.
The time related changes in protein oxidation and

enzyme activity following termination of twice daily
dosing with either 10 mg PBN/kg (FIGS. 3A, B, and C)
or 32 mg PBN/kg (FIGS. 4A, B, and C) are also shown
by these ?gures. The results demonstrate that the effect
of the PBN is unaltered one to three days after termina
tion of treatment twice daily with the PBN, although
the PBN itself has a half-life of three hours. At seven

days, the enzyme levels are altered by approximately
50%. At fourteen days, the oxidized enzymes have
returned to approximately their pre-treatment levels.

Example 3

mals are placed into the radial arm maze, are tested once
and these differences are reliable on retest.

Modi?cations and variations of the method and com

position for the treatment of aging will be obvious to
those skilled in the art from the foregoing detailed de
scription. Such modi?cations and variations are in
tended to come within the scope of the appended
claims.
We claim:
1. A method of improving short term memory in a

patient suffering from short term memory loss compris
ing administering to said patient an effective amount of
a composition capable of improving short term mem
ory, said composition having as the active ingredient a

compound selected from the group consisting of a-phe
nyl t-butyl nitrone (PBN) and derivatives thereof se
lected from the group consisting of hydroxy PBNs,

PBN esters, acetoxy PBNs, alkyl PBNs, alkoxy PBNs,
and phenyl PBNs having spin trapping activity; and a
pharmaceutically acceptable carrier therefor.

Demonstration of correlation between effect of PBN on
2. The method of claim 1 wherein the active agent is
brain enzymes and memory
a
spin-trapping
derivative of PBN having the formula:
FIG. 5 demonstrates that there is a functional coun
terpart to such treatment. Young and old gerbils were 45
tested in a radial arm maze test for spacial and short

H

term memory. Animals were placed in the central hub
of a eight armed radial maze and given access to explore
all eight arms of the radial arm maze. When the animal

X

O

C=N+
Y

completed the test of exploring each of the eight arms, 50
the animal was removed from the maze. The number of

times that the animals reentered arms that had been

wherein:
X is phenyl or

previously entered was counted as an error. Under ideal

conditions animals will enter each one of the eight arms

(0K)”

but not reenter any of the arms. In many cases young 55

adult gerbils (young) entered each of the arms without
reentering any of the arms. The time required to enter
all eight arms was also recorded but did not appear to

determine'the ef?ciency of the short term memory task.
As can be seen in FIG. 6, young gerbils made an aver

age of 2.83 errors during the test session. In contrast. old
gerbils made an average of 6.82 errors, which is a highly
signi?cant difference between the two groups.

wherein

R is H,
0

Young adult gerbils exposed to a period of transient

II

ischemia, which is also an oxidizing process, make a 65

Z—C—,

substantial number of errors with an average value of 15
errors in such a test session. During the post ischemic

period, there is a marked build up of carbonyl protein

or

Z;

or

/
—CH=N
\

,

Y

and n is a whole integer from 1 to 5; or
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o

H

NH—g-Z;

o-

(I)

C=N+
5

Y is a tert-butyl group that can be hydroxylated or

Y

Whe1'_ein¢

acetylated on one or more positions; phenyl; or
i

X

X 15 phenyl or
10

ow

(011)”
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wherein
W is

wherein
R is H,
20

II
II
II
C—CH3, NH-C-Z, C-.-OZ,

O

0

II
_ /
_‘Z_C", 01‘ Z; Or _CH—N+\

,
Y

or Z; and
Z is a C1 to C5 straight or branched alkyl group.

25

and n is a whole integer from 1 to 5; or

3. The method of claim 1 wherein the active ingredi
ent is a-phenyl t-butyl nitrone.
4. The method of claim 1 wherein the PBN or deriva
tives thereof is provided in a dosage of between 1 and

300 mg/kg body weight.

30

5. The method of claim 4 wherein the PBN or deriva
tives thereof is provided in a dosage of between 1 and 10

Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

mg/kg body weight.
6. The method of claim 1 wherein the active agent is
provided in combination with a pharmaceutical carrier 35
selected from the group consisting of microspheres,

OW

liposomes, immobilizing substrates, polymeric matrices
and buffering agents.
7. The method of claim 1 wherein the short term
memory loss is associated with ischemia and wherein
wherein
the route of administering is intravenous.
W is
8. The method of claim 1 wherein the short term
memory loss is associated with progressive neuronal
O
O
0
45
II
II
II
loss and wherein the route of administering is oral.
0-01-13,
NH-C-Z,
c-oz,
9. The method of claim 8 wherein the progressive
neuronal loss is due to Parkinson’s disease.
or Z; and
10. The method of claim 8 wherein the progressive
Z
is a C1 to C5 straight or branched alkyl group; or
neuronal loss is due to senile dementia.
(b)
at least one other alpha-phenyl t-butyl nitrone
11. The method of claim 8 wherein the progressive
(PBN)
derivative selected from the group consist
neuronal loss is due to Alzheimer’s disease.
ing of hydroxy PBNs, PBN esters, acetoxy PBNs,
12. The method of claim 1 wherein X is
55

(011)”

alkyl PBNs, alkoxy PBNs and phenyl PBNs having
spin-trapping activity in vivo in tissue,

optionally in association with a pharmaceutically

acceptable carrier.
v

15. A method according to claim 14 wherein said
compound is provided in combination with a pharma
ceutical carrier.
and R is H or Z.
60
16. A method according to claim 14 wherein said
13. The method of claim 12 wherein Y is a tert-butyl
compound is provided in combination with a pharma
group.
ceutical carrier selected from the group consisting of
14. A method for improving short term memory in a

microspheres, liposomes, immobilizing substrates, poly

patient suffering from short term memory loss compris- 65 meric matrices, and buffering agents.
ing administering to said patient an effective amount of
17. A method according to claim 14 wherein said
a compound selected from

(a) at least one compound of formula (I):

'

compound is administered in a dosage of from 1 to 300

mg/kg body weight.

17
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18. A method according to claim 14 wherein said
compound is administered in a dosage of from 1 to 10

18

24. The method of claim 14 wherein Y is tert-butyl.
25. The method of claim 14 wherein X is

mg/kg body weight.
19. The method of claim 14 wherein the short term
memory loss is associated with ischemia.
20. The method of claim 14 wherein the short term
memory loss is associated with progressive neuronal
loss.
21. The method of claim 20 wherein the progressive
neuronal loss is due to Parkinson’s disease.
22. The method of claim 20 wherein the progressive

and R is H or Z.

neuronal loss is due to senile dementia.

23. The method of claim 20 wherein the progressive
neuronal loss is due to Alzheimer’s disease.
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26. The method of claim 25 wherein Y is tert-butyl.
27. The method of claim 25 wherein R is H.
28. The method of claim 25 wherein R is Z.
29. The method of claim 14 wherein when Y is tert
butyl then X is not phenyl.
*
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